Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amylin/Lilly Eye Byetta sNDA As Monotherapy In 1H 2008

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly tells DAILY that as monotherapy for type 2 diabetes, exenatide could be prescribed to patients earlier in treatment.

You may also be interested in...



Amylin CEO: Firm Can Do Better With Byetta

Diabetes drug so far has failed to catch on with primary-care docs.

Amylin CEO: Firm Can Do Better With Byetta

Diabetes drug so far has failed to catch on with primary-care docs.

Lilly Acquires Diabetes Candidates In Deal With Transition Therapeutics

After ending its efforts to develop inhaled insulin, Lilly rebuilds in-house pipeline of diabetes candidates.

Related Content

Topics

UsernamePublicRestriction

Register

PS065590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel